Why did FDA approve AstraZeneca camizestrant despite expert panel resistance?

The article says the FDA granted accelerated approval to AstraZeneca’s camizestrant in a rare break from its own expert panel. It frames the move as a consequential signal that the agency may be willing to back ctDNA-guided, biomarker-directed treatment approaches in breast cancer even amid a contested review.